FDA approves Pfizer drug for rare blood cancer

Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.

Pfizer's Bosulif is a daily pill to treat patients with a specific genetic variation. The disease is one of four types of the blood cancer, and accounts for about 15 percent of leukemia cases.

The disease, which usually affects seniors, causes the bone marrow to produce unhealthy that do not grow and die like normal cells. Instead, the cells buildup in the bone marrow and crowd out healthy cells that are needed to fight off infections.

An estimated 5,430 people will be diagnosed with this year, according to the FDA.


Explore further

Marqibo approved for rare leukemia

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: FDA approves Pfizer drug for rare blood cancer (2012, September 4) retrieved 9 December 2019 from https://medicalxpress.com/news/2012-09-fda-pfizer-drug-rare-blood.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments